The CSL share price is a sleeping dividend giant. Here's why

CSL shares aren't considered serious dividend payers. But this could be a costly mistake.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The ASX is home to many dividend heavyweights
  • But CSL shares aren't usually considered among these
  • Here's why that assumption may be a mistake

 The CSL Limited (ASX: CSL) share price has been a staple of the S&P/ASX 200 Index (ASX: XJO) for decades now. In fact, CSL has spent its time over the past decade or so climbing up from the middle of the ASX 200 pack to the number three position on the Index that it now occupies.

But unlike its fellow top ASX 200 shares, such as BHP Group Ltd (ASX: BHP) or the big four banks, CSL has never been regarded as a dividend heavyweight. 

A quick look at the CSL share price today will probably tell you why. Right now, CSL has a trailing dividend yield of just 1.11%. That only comes partially franked too.

In stark contrast, BHP shares currently offer a fully-franked trailing yield of 8.86% right now. Commonwealth Bank of Australia (ASX: CBA) is at a fully-franked 4.2%, while Westpac Banking Corp (ASX: WBC) offers 5.62%.

So dividend-chasing income investors probably won't take too long in deciding which shares to have in their portfolios. But those investors might want to take a second look because all is not quite as it seems at first glance. 

Yes, you won't get as much dividend income upfront buying CSL shares as you would BHP or one of the big four banks. But CSL could well be a sleeping divided giant and one whose dividends might approach, or even exceed, the level of income offered by ASX's other heavyweights in just a few years.

Here's why.

A tired healthcare or lab worker sleeps on her desk

Image source: Getty Images

Why the CSL share price could be a sleeping dividend giant

CSL first started paying its investors dividends back in 2013. The company's very first dividend payment was a final dividend worth 52 US cents per share. In 2014, the company doled out annual dividend payments worth US$1.13 per share.

But just five years later in 2019, CSL was up to paying out US$1.85 in dividends per share. By 2022, this had risen again to a total of US$2.22 per share.

In US dollar terms, CSL has consistently raised its annual dividend every single year since 2013. Because of currency exchange rates, we can't say the same for its dividends in Aussie dollar terms. But the trend is clear.

In 2023 so far, this trend has continued too. The interim dividend that investors received only earlier this month came in at US$1.07 per share. That was a significant hike over 2022's corresponding payment of US$1.04 per share.

Between 2014 and 2022, CSL's annual dividend rocketed by a cumulative 96.5%. If CSL's dividends keep rising at this level over the next eight years, investors will be bagging US$4.36 in dividends per share by the year 2030. That's $6.54 per share in Australian dollars at the current exchange rate.

If that were to occur (which is by no means guaranteed), it would be highly lucrative for long-term investors, and would finally make CSL an ASX dividend heavyweight.

So this just proves that you can't judge an ASX divided share by the yield on its cover. By the time the 'sleeping giant' awakens, it might be too late to nab the shares at a good share price.

 

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Westpac Banking. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in suit and tie is smug about his suitcase bursting with cash.
Healthcare Shares

This ASX healthcare stock is up 70% in a year and climbing again today

Another strong quarter keeps the Cogstate stock in focus.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX healthcare stock could more than double according to Canaccord Genuity

It's shaping up as a big year for this drug developer.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off

Neuren shares jump after DAYBUE STIX expands across the US.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

After a 30% 2026 slide, Pro Medicus shares are rocketing again

Pro Medicus shares jump after another major contract win.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Could the CSL share price reach $200 in 2026?

The biotech's shares have had a tough run, but the long-term story may not be broken.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Pro Medicus announces $23m US contract

Pro Medicus has signed a $23 million, five-year cloud imaging contract with University of Maryland Medical System.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

2 classy ASX healthcare stocks to buy before the next market surge

If sentiment shifts, these global powerhouses could lead the rally.

Read more »